EE200100136A - Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon - Google Patents

Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon

Info

Publication number
EE200100136A
EE200100136A EEP200100136A EEP200100136A EE200100136A EE 200100136 A EE200100136 A EE 200100136A EE P200100136 A EEP200100136 A EE P200100136A EE P200100136 A EEP200100136 A EE P200100136A EE 200100136 A EE200100136 A EE 200100136A
Authority
EE
Estonia
Prior art keywords
cognitive
medicament
agents
manufacture
treatment
Prior art date
Application number
EEP200100136A
Other languages
English (en)
Inventor
Leonce Irma De Nijs Paul
Louis Julien Parys Wim
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of EE200100136A publication Critical patent/EE200100136A/et

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
EEP200100136A 1998-10-16 1999-10-12 Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon EE200100136A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP98203454 1998-10-16
PCT/EP1999/007804 WO2000023057A2 (en) 1998-10-16 1999-10-12 Atypical antiphsychotic in combination with acetylcholinesterase inhibitor for improving cognition

Publications (1)

Publication Number Publication Date
EE200100136A true EE200100136A (et) 2002-06-17

Family

ID=8234219

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200100136A EE200100136A (et) 1998-10-16 1999-10-12 Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon

Country Status (20)

Country Link
EP (1) EP1121131A2 (et)
JP (1) JP2002527469A (et)
KR (1) KR20010072878A (et)
CN (1) CN1367697A (et)
AU (1) AU6472799A (et)
BG (1) BG105302A (et)
BR (1) BR9914419A (et)
CA (1) CA2345767A1 (et)
EE (1) EE200100136A (et)
HK (1) HK1039745A1 (et)
HR (1) HRP20010262A2 (et)
HU (1) HUP0103781A3 (et)
ID (1) ID28441A (et)
IL (1) IL142588A0 (et)
NO (1) NO20011403L (et)
PL (1) PL348107A1 (et)
SK (1) SK4592001A3 (et)
TR (1) TR200101082T2 (et)
WO (1) WO2000023057A2 (et)
ZA (1) ZA200103081B (et)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006201188B2 (en) * 2001-02-05 2007-11-15 Novartis Ag New use of iloperidone
GB0102841D0 (en) * 2001-02-05 2001-03-21 Novartis Ag Organic compounds
ES2436439T3 (es) 2001-10-30 2014-01-02 Novartis Ag Formulaciones de medicamento de liberación lenta de iloperidona con un polímero
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
EP1824848A1 (en) * 2004-12-10 2007-08-29 Abbott Laboratories Fused bicycloheterocycle substituted quinuclidine derivatives
WO2005065645A2 (en) * 2003-12-31 2005-07-21 Actavis Group Hf Donepezil formulations
EP2089383B1 (en) 2006-11-09 2015-09-16 Probiodrug AG 3-hydr0xy-1,5-dihydr0-pyrr0l-2-one derivatives as inhibitors of glutaminyl cyclase for the treatment of ulcer, cancer and other diseases
US9126987B2 (en) 2006-11-30 2015-09-08 Probiodrug Ag Inhibitors of glutaminyl cyclase
AU2008220785B2 (en) 2007-03-01 2013-02-21 Vivoryon Therapeutics N.V. New use of glutaminyl cyclase inhibitors
JP5667440B2 (ja) 2007-04-18 2015-02-12 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤としてのチオ尿素誘導体
MX2007008642A (es) * 2007-07-16 2009-02-25 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente inhibidor reversible de la enzima colinesterasa, indicada para el control y tratamiento de trastornos psicoticos y demencias.
EA202092673A3 (ru) 2010-02-09 2021-05-31 Дзе Джонс Хопкинс Юниверсити Способы и композиции для улучшения когнитивной функции
WO2011107530A2 (en) 2010-03-03 2011-09-09 Probiodrug Ag Novel inhibitors
JP5688745B2 (ja) 2010-03-10 2015-03-25 プロビオドルグ エージー グルタミニルシクラーゼ（ｑｃ、ｅｃ２．３．２．５）の複素環阻害剤
WO2011131748A2 (en) 2010-04-21 2011-10-27 Probiodrug Ag Novel inhibitors
EP2686313B1 (en) 2011-03-16 2016-02-03 Probiodrug AG Benzimidazole derivatives as inhibitors of glutaminyl cyclase
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
AU2014228512A1 (en) 2013-03-15 2015-10-01 Agenebio, Inc. Methods and compositions for improving cognitive function
WO2014144663A1 (en) 2013-03-15 2014-09-18 The Johns Hopkins University Methods and compositions for improving cognitive function
CA2986598C (en) 2015-05-22 2023-09-26 Agenebio, Inc. Extended release pharmaceutical compositions of levetiracetam
ES2812698T3 (es) 2017-09-29 2021-03-18 Probiodrug Ag Inhibidores de glutaminil ciclasa

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5336675A (en) * 1991-05-14 1994-08-09 Ernir Snorrason Method of treating mania in humans
EP0584185B1 (en) * 1991-05-14 1999-08-11 Ernir Snorrason Treatment of fatigue syndrome with cholinesterase inhibitors
AU8778498A (en) * 1997-08-11 1999-03-01 University Of South Florida Research Foundation, Inc. Nicotine antagonists for nicotine-responsive neuropsychiatric disorders
DE1073432T1 (de) * 1998-04-14 2002-02-07 The General Hospital Corp., Boston Verwendung von glycinrezeptoragonisten und glycinaufnahmeinhibitoren zur behandlung neuropsychiatrischer beschwerden

Also Published As

Publication number Publication date
NO20011403D0 (no) 2001-03-20
HUP0103781A2 (hu) 2002-03-28
HRP20010262A2 (en) 2002-06-30
AU6472799A (en) 2000-05-08
NO20011403L (no) 2001-03-20
KR20010072878A (ko) 2001-07-31
BG105302A (en) 2001-11-30
EP1121131A2 (en) 2001-08-08
BR9914419A (pt) 2001-06-26
CN1367697A (zh) 2002-09-04
ZA200103081B (en) 2002-07-12
WO2000023057A2 (en) 2000-04-27
ID28441A (id) 2001-05-24
HK1039745A1 (zh) 2002-05-10
HUP0103781A3 (en) 2003-09-29
PL348107A1 (en) 2002-05-06
SK4592001A3 (en) 2001-12-03
JP2002527469A (ja) 2002-08-27
WO2000023057A3 (en) 2000-07-27
TR200101082T2 (tr) 2001-09-21
CA2345767A1 (en) 2000-04-27
IL142588A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
EE200100136A (et) Atsetüülkoliini esteraasi inhibiitori ja psühhoosivastase toimeaine kasutamine ravimi valmistamiseks, mis on ette nähtud kognitsiooni- ja psühhoosihäirete raviks, ning neid aineid sisaldav farmatseutiline kompositsioon
EE04613B1 (et) Sahhariidijääkidega asendatud 1,4-bensotiasepiin-1,1-dioksiidi derivaadid, meetod nende valmistamiseks, ühendite kasutamine ning neid sisaldav ravim
HUP0103856A3 (en) Pharmaceutical composition for the treatment of acute disorders
AR028426A1 (es) Una composicion farmaceutica y procedimiento de tratamiento de enfermedades de disfunsion cognitiva en un mamifero
NO20006630D0 (no) Farmasöytisk sammensetning for behandlingen av diabetes
HUP0302476A3 (en) Use of acetylcholinesterase inhibitors and gabaainverse agonists for the treatment of cognitive disorders and for preparation of pharmaceutical compositins
IL147217A0 (en) New spirooxindole derivatives and pharmaceutical compositions containing the same for treatment of pain
PT956858E (pt) Composicoes farmaceuticas contendo lactobacilos para o tratamento de infeccoes vaginais
EE200200274A (et) Pürrolidiinatseetamiidi derivaadi kasutamine ravimi valmistamiseks, mis on ette nähtud kesknärvisüsteemi häirete ravimiseks, ja farmatseutiline kompositsioon
PL341343A1 (en) Composition for treating respiratory diseases and dermatoses containing at least one leucotriene antagonist and at least one antihistaminic agent
DE69836008D1 (de) Zusammensetzung und behandlungsmittel
NO20001001D0 (no) Poly (ADP-ribose) polymerase ("PARP") inhibitorer, fremgangsmõte og farmasøytiske sammensetninger for behandling av neurale og kardiovaskulære vevskader
DE60023792D1 (de) Karmin und Karamel enthaltende selbstbräunende Zusammensetzung
EE200100179A (et) Farmatseutilised agendid Parkinsoni tõve, ADHD jamikroadenoomide raviks
EE200300167A (et) Amidoalküülpiperidiini ja -piperasiini derivaadid, neid sisaldav farmatseutiline kompositsioon ningühendite kasutamine närvisüsteemi häirete raviks
HUP9802795A3 (en) Pharmaceutical compositions containing beta-adrenergic agent and anorectic agent for the treatment of corpulence
CA2284551A1 (en) New therapeutic combinations of mirtazapine and antipsychotic agents, for the treatment or prophylaxis of psychotic disorders
HUP9902405A3 (en) Pharmaceutical compositions containing a serotonin antagonist for the treatment of the common cold or allergic rhinitis
NO20011695L (no) Farmasöytisk sammensetning med langvarig frigivelse og fremgangsmåte for å frigi farmasöytisk aktivt middel
EP1177798A3 (en) A pharmaceutical composition for the treatment of attention deficit hyperactivity disorder(ADHD) comprising a nicotine receptor partial agonist and anti-ADHD agent
NZ513650A (en) Pharmaceutical composition for the treatment of urinary incontinence, motion sickness and vertigo
HUP0301830A3 (en) Pharmaceutical composition containing a combination of fbpase inhibitors and antidiabetic agents useful for the treatment of diabetes
EE04493B1 (et) Tsüklopenteeni derivaadid, neid sisaldav farmatseutiline kompositsioon ning ühendite kasutamine ravimina inimestel esinevate motiliini retseptoriga seotud häirete raviks
EE200200590A (et) Bradükardiaalsete toimeainete kasutamine hüpertroofiaga seotud müokardiaalsete haiguste ravimiseks ja uudsed ravimikombinatsioonid
UA66872C2 (uk) Сполука, яка є памоатом оланзапіну або його сольватом, та спосіб лікування психотичних розладів